Fatouros has extensive experience as pharmaceutical analyst and portfolio manager and has a PhD in pharmaceuticals. The funds will be managed based on a fundamental investment process where, among other things, analysis of the companies’ management and business model are key elements. Previously, the fund was managed based on a quantitative investment process.
The following funds/sub funds and all their share classes are affected:
|SEB Concept Biotechnology||SEB Fund 3 – SEB Medical Fund|
|C (EUR), ISIN LU0385485148
D (EUR), ISIN LU0118405827
UC (EUR), ISIN LU2249630927
|D (USD), ISIN LU0047324214
UD (USD), ISIN LU2249630331